The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2017 | What is durvalumab’s future as a treatment option in lung cancer?
Luis Paz-Ares, MD, from The University Hospital 12 de Octubre, Madrid, Spain talks to us about the PACIFIC trial (NCT02125461), a Phase III study assessing the efficacy of durvalumab in the treatment of unresectable non-small cell lung cancer following chemoradiation. Prof. Paz-Ares talks us through the results of the trial and explains what these tell us about the future of durvalumab as a treatment option. He also discusses when follow-up assessments of the drug will be made. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.
